Carmeli B., Casali P.G., Goldbraich A., Kent C., Licitra L., Locatelli P

Carmeli B., Casali P.G., Goldbraich A., Kent C., Licitra L., Locatelli P., Restifo N.,
Rinott R., Sini E., Torresani M., Waks Z.: Evicase: An Evidence-based Case Structuring
Approach for Personalized Healthcare. Stud Health Technol Inform 2012; 180: 604-608
[IF 0]
Casali P.G., Fumagalli E., Gronchi A.: Adjuvant Therapy of Gastrointestinal Stromal
Tumors (GIST). Curr Treat Options Oncol 2012; 13: 277-284 [IF 2,684]
Casali P.G.: Histology- and non-histology-driven therapy for treatment of soft tissue
sarcomas. Ann Oncol 2012; 23: Suppl 10 x: 167-169 [IF 6,425]
Cassier P.A., Fumagalli E., Rutkowski P., Schöffski P., Van Glabbeke M., DebiecRychter M., Emile J.F., Duffaud F., Martin-Broto J., Landi B., Adenis A., Bertucci F.,
Bompas E., Bouchè O., Leyvraz S., Judson I., Verweij J., Casali P.G., Blay J.Y.,
Hohenberger P., for the European Organisation for, Research and Treatment of Cancer:
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated
Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. Clin Cancer Res
2012; 18: 4458-4464 [IF 7,742]
Cassier P.A., Gelderblom H., Stacchiotti S., Thomas D., Maki R.G., Kroep J.R., van
der Graaf W.T., Italiano A., Seddon B., Domont J., Bompas E., Wagner A.J., Blay J.Y.:
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic
tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 2012; 118: 16491655 [IF 4,771]
Collini P., Negri T., Barisella M., Palassini E., Tarantino E., Pastorino U., Gronchi A.,
Stacchiotti S., Pilotti S.: High-grade Sarcomatous Overgrowth in Solitary Fibrous
Tumors: A Clinicopathologic Study of 10 Cases. Am J Surg Pathol 2012; 36: 1202-1215
[IF 4,352]
Colombo C., Miceli R., Collini P., Radaelli S., Palassini E., Stacchiotti S., Fiore M.,
Mariani L., Casali P.G., Gronchi A.: Leiomyosarcoma and sarcoma with myogenic
differentiation: Two different entities or 2 faces of the same disease? Cancer 2012; 118:
5349-5357 [IF 4,771]
Crocetti E., Trama A., Stiller C., Caldarella A., Soffietti R., Jaal J., Weber D.C., Ricardi
U., Slowinski J., Brandes A., Contiero P., Casali P.G., Gatta G., Gronchi A., Licitra L.,
RARECARE working group: Epidemiology of glial and non-glial brain tumours in
Europe.1 Eur J Cancer 2012; 48: 1532-1542 [IF 5,536]
Demetri G.D., Garrett C.R., Schoffski P., Shah M.H., Verweij J., Leyvraz S., Hurwitz
H.I., Pousa A.L., Le Cesne A., Goldstein D., Paz-Ares L., Blay J.Y., McArthur G.A.,
Xu Q., Huang X., Harmon C.S., Tassell V., Cohen D.P., Casali P.G.: Complete
Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of
Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure. Clin
Cancer Res 2012; 18: 3170-3179 [IF 7,742]
Faivre J., Trama A., De Angelis R., Elferink M., Siesling S., Audisio R., Bosset J.F.,
Cervantes A., Lepage C., Contiero P., Casali P.G., Gatta G., Gronchi A., Licitra L., The
RARECARE Working Group: Incidence, prevalence and survival of patients with rare
epithelial digestive cancers diagnosed in Europe in 1995-2002. Eur J Cancer 2012; 48:
1417-1424 [IF 5,536]
Ferrari A., Bertulli R.: At the crossroads of molecular biology, pathology and the clinic.
Expert Rev Anticancer Ther 2012; 12: 725-728 [IF 2,652]
Ferrari S., Ruggeri P., Cefalo G., Tamburini A., Capanna R., Fagioli F., Comandone A.,
Bertulli R., Bisogno G., Palmerini E., Alberghini E., Parafioriti A., Linari A., Picci P.,
Bacci G.: Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin
With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian
Sarcoma Group Trial ISG/OS-1. J Clin Oncol 2012; 30: 2112-2118 [IF 18,372]
Fiore M., Colombo C., Locati P., Berselli M., Radaelli S., Morosi C., Casali P.G.,
Gronchi A.: Surgical technique, morbidity, and outcome of primary retroperitoneal
sarcoma involving inferior vena cava. Ann Surg Oncol 2012; 19: 511-518 [IF 4,166]
Gatta G., Ferrari A., Stiller C.A., Pastore G., Bisogno G., Trama A., Capocaccia R.,
Casali P.G., Gronchi A., Licitra L., The RARECARE Working Group: Embryonal
cancers in Europe. Eur J Cancer 2012; 48: 1425-1433 [IF 5,536]
Grignani G., Palmerini E., Delie P., Asaftei S.D., D'Ambrosio L., Pignochino Y., Mercuri
M., Picci P., Fagioli F., Casali P.G., Ferrari S., Aglietta M.: A phase II trial of sorafenib
in relapsed and unresectable high-grade osteosarcoma after failure of standard
multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012; 23: 508-516 [IF
6,425]
Gronchi A., Frustaci S., Mercuri M., Martin J., Lopez-Pousa A., Verderio P., Mariani L.,
Valagussa P., Miceli R., Stacchiotti S., Dei Tos P., De Paoli A., Longhi A., Poveda A.,
Quagliolo V., Comandone A., Casali P.G., Picci P.: Short, full-dose adjuvant
chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the
Italian Sarcoma group and the Spanish Sarcoma Group. J Clin Oncol 2012; 30: 850-856
[IF 18,372]
Gronchi A., Miceli R., Colombo C., Stacchiotti S., Collini P., Mariani L., Sangalli C.,
Radaelli S., Sanfilippo G.R., Fiore M., Casali P.G.: Frontline extended surgery is
associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue
sarcomas. Ann Oncol 2012; 23: 1067-1073 [IF 6,425]
Italiano A., Cioffi A., Coco P., Maki R.G., Schoffski P., Rutkowski P., Le Cesne A.,
Duffaud F., Adenis A., Isambert N., Bompas E., Blay J.Y., Casali P.G., Keohan M.L.,
Toulmonde M., Antonescu C.R., Dwbiec-Rychter M., Coindre J.M., Bui B.: Patterns of
Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal
Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. Ann Surg
Oncol 2012; 19: 1551-1559 [IF 4,166]
Le Cesne A., Cresta S., Maki R.G., Blay J.Y., Verweij J., Poveda A., Casali P.G.,
Balana C., Schöffski P., Grosso F., Lardelli P., Nieto A., Alfaro V., Demetri G.D.: A
retrospective analysis of antitumour activity with trabectedin in translocation-related
sarcomas. Eur J Cancer 2012; 48: 3036-3044 [IF 5,536]
Mallone S., De Vries E., Guzzo M., Midena E., Verne J., Coebergh J.W., MarcosGragera R., Ardanaz E., Martinez R., Chirlaque M.D., Navarro C., Virgili G., Contiero
P., Casali P.G., Gatta G., Gronchi A., Licitra L., Trama A., The RARECARE WG:
Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin
carcinomas in Europe. Eur J Cancer 2012; 48: 1167-1175 [IF 5,536]
Mandalà M., Grosso F., Vitalini C., Corradino I., Sanfilippo G.R., Colombini S., Clerici
M., Labianca R., De Pascale A., Marsoni S.: Venous thromboembolism is a relevant and
underestimated adverse event in cancer patients treated in phase I studies. Br J Cancer
2012; 107: 612-616 [IF 5,042]
Negri T., Brich S., Conca E., Bozzi F., Orsenigo M., Stacchiotti S., Alberghini M.,
Mauro V., Gronchi A., Dusio G.F., Pelosi G., Picci P., Casali P.G., Pierotti M.A., Pilotti
S.: Receptor tyrosine kinase pathway analysis sheds light on similarities between clearcell sarcoma and metastatic melanoma. Genes Chromosom Cancer 2012; 51: 111-126
[IF 3,306]
Reichardt P., Blay J.Y., Boukovinas I., Brodowicz T., Broto J.M., Casali P.G., Decatris
M., Eriksson M., Gelderblom H., Kosmidis P., Le Cesne A., Pousa A.L., Schlemmer
M., Verweij J., Joensuu H.: Adjuvant therapy in primary GIST: state-of-the-art. Ann
Oncol 2012; 23: 2776-2781 [IF 6,425]
Rinott R., Torresani M., Bertulli R., Goldsteen A., Casali P.G., Carmeli B., Slonim N.:
Automatic Detection of Inconsistencies between Free Text and Coded Data in Sarcoma
Discharge Letters. Stud Health Technol Inform 2012; 180: 661-666 [IF 0]
Rivoltini L., Marrari A., Castelli C., Villa S., Valdagni R.: Don't run before you can walk.
(Letter) Nat Rev Urol 2012; 9: 602-603 [IF 4,415]
Siesling S., van der Zwan J.M., Izarzugaza I., Jaal J., Treasure T., Foschi R., Ricardi U.,
Groen H., Tavilla A., Ardanaz E., Casali P.G., Gatta G., Gronchi A., Licitra L., Trama
A., Contiero P., on behalf of the RARECARE working group: Rare thoracic cancers,
including peritoneum mesothelioma. Eur J Cancer 2012; 48: 949-960 [IF 5,536]
Stacchiotti S., Dagrada G.P., Morosi C., Negri T., Romanini A., Pilotti S., Gronchi A.,
Casali P.G.: Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. Clin
Sarcoma Res 2012; 2: 22 [IF 0]
Stacchiotti S., Longhi A., Ferraresi V., Grignani G., Comandone A., Stupp R., Bertuzzi
A., Tamborini E., Pilotti S., Messina A., Spreafico C., Gronchi A., Amore P., Vinaccia
V., Casali P.G.: Phase II Study of Imatinib in Advanced Chordoma. J Clin Oncol 2012;
30: 914-920 [IF 18,372]
Stacchiotti S., Negri T., Libertini M., Palassini E., Marrari A., De Troia b., Gronchi A.,
Dei Tos A.P., Morosi C., Messina A., Pilotti S., Casali P.G.: Sunitinib malate in solitary
fibrous tumor (SFT). Ann Oncol 2012; 23: 3171-3179 [IF 6,425]
Stacchiotti S., Palassini E., Sanfilippo G.R., Vincenzi B., Arena M.G., Bochicchio A.M.,
De Rosa P., Nuzzo A., Turano S., Morosi C., Dei Tos A.P., Pilotti S., Casali P.G.:
Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the
Italian Rare Cancer Network. Ann Oncol 2012; 23: 501-508 [IF 6,425]
Stacchiotti S., Verderio P., Messina A., Morosi C., Collini P., Llombart-Bosch A.,
Martin J., Comandone A., Cruz J., Ferraro A., Grignani G., Pizzamiglio S., Quagliolo V.,
Picci P., Frustaci S., Dei Tos A.P., Casali P.G., Gronchi A.: Tumor response
assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated
with chemotherapy. Cancer 2012; 118: 5857-5866 [IF 4,771]
The ESMO European Sarcoma Network Working Group, Casali P.G., Ferrari A.,
Gronchi A., Stacchiotti S.: Bone sarcomas: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl 7): 100-109 [IF 6,425]
The ESMO European Sarcoma Network Working Group, Casali P.G., Ferrari A.,
Gronchi A., Stacchiotti S.: Gastrointestinal stromal tumors: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 7): 49-55
[IF 6,425]
The ESMO European Sarcoma Network Working Group, Casali P.G., Ferrari A.,
Gronchi A., Stacchiotti S.: Soft tissue and visceral sarcomas: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 7): 92-99
[IF 6,425]
Trama A., Mallone S., Ferretti S., Meduri F., Capocaccia R., Gatta G., Berrino F.,
Casali P.G., Licitra L., and the RITA working Group: The burden of rare cancers in
Italy: the surveillance of rare cancers in Italy (RITA) project. Tumori 2012; 98: 550-558
[IF 0,606]
Trama A., Mallone S., Nicolai N., Necchi A., Schaapveld M., Gietema J., Znaor A.,
Ardanaz E., Berrino F., Casali P.G., Gatta G., Gronchi A., Licitra L., The RARECARE
Working group: Burden of testicular, paratesticular and extragonadal germ cell tumours
in Europe. Eur J Cancer 2012; 48: 159-169 [IF 5,536]
van der Graaf W.T., Blay J.Y., Chawla S.P., Kim D.W., Bui-Nguyen B., Casali P.G.,
Schoffski P., Aglietta M., Staddon A.P., Beppu Y., Le Cesne A., Gelderblom H.,
Judson I.R., Araki N., Ouali M., Marreaud S., Hodge R., Dewji M.R., Coens C.,
Demetri G.D., Fletcher C.D., Dei Tos A.P., Hohenberger P., EORTC Soft Tissue and
Bone Sarcoma Group, PALETTE study group: Pazopanib for metastatic soft-tissue
sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet 2012; 379: 1879-1886 [IF 38,278]
van der Zwan J.M., Mallone S., van Dijk B., Bielska-Lasota M., Otter R., Foschi R.,
Baudin R., Links T.P., Tagliabue G., Casali P.G., Gronchi A., Trama A., The
RARECARE WG: Carcinoma of endocrine organs: Results of the RARECARE project.
Eur J Cancer 2012; 48: 1923-1931 [IF 5,536]
Van Dijk B.A.C., Gatta G., Capocaccia R., Pierannunzio D., Strojan P., Licitra L., Casali
P.G., Gronchi A., Ruzza M., Trama A., The RARECARE Working Group: Rare
cancers of the head and neck area in Europe. Eur J Cancer 2012; 48: 783-796 [IF 5,536]
Vincenzi B., Santini D., Schiavon G., Frezza A.M., Silletta M., Crucitti P., Casali P.G.,
Dei Tos A.P., Rossi S., Rizzo S., Badalamenti G., Tomasino R.M., Russo A., Butrynski
J.E., Tonini G.: PML expression in soft tissue sarcoma: Prognostic and predictive value
in alkylating agents/antracycline-based first line therapy. J Cell Physiol 2012; 227: 16571662 [IF 3,874]
Visser O., Adolfsson J., Rossi S., Verne J., Gatta G., Maffezzini M., Franks K.N.,
Casali P.G., Gronchi A., Licitra L., Trama A.: Incidence and survival of rare urogenital
cancers in Europe. Eur J Cancer 2012; 48: 456-464 [IF 5,536]
2011
Casali P.G., Sanfilippo G.R.: Uterine sarcomas: a multidisciplinary challenge. Eur J Cancer 2011; 47:
Suppl. 3: 326-327
Casali P.G.: Medical oncology: the long-awaited prize of recognition. (Editorial) Ann Oncol 2011; 22:
1695-1697
Da Riva L., Bozzi F., Mondellini P., Miccichè F., Fumagalli E., Vaghi E., Tarantino E., Huber V., Gronchi
A., Tamborini E., Pierotti M.A., Pilotti S., Bongarzone I.: Proteomic detection of a large amount of
SCGFα in the stroma of GISTs after imatinib therapy. J Transl Med 2011; 9: 158
Dileo P., Pricl S., Tamborini E., Negri T., Stacchiotti S., Gronchi A., Posocco P., Laurini E., Coco P.,
Fumagalli E., Casali P.G., Pilotti S.: Imatinib response in two GIST patients carrying two hitherto
functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling
study. Int J Cancer 2011; 128: 983-990
Gatta G., van der Zwan J.M., Casali P.G., Siesling S., Dei Tos A.P., Kunkler I., Otter R., Licitra L.,
Mallone S., Tavilla A., Trama A., Capocaccia R., The RARECARE working group: Rare cancers are not
so rare: The rare cancer burden in Europe. Eur J Cancer 2011; 47: 2493-2511 [IF 4,944]
Grignani G., Palmerini E., Stacchiotti S., Boglione A., Ferraresi V., Frustaci S., Comandone A., Casali
P.G., Ferrari S., Aglietta M.: A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable
chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group
study. Cancer 2011; 117: 826-831
Gronchi A., Miceli R., Colombo C., Collini P., Stacchiotti S., Olmi P., Mariani L., Bertulli R., Fiore M.,
Casali P.G.: Primary extremity soft tissue sarcomas: outcome improvement over time at a single
institution. Ann Oncol 2011; 22: 1675-1681
Italiano A., Laurand A., Laroche A., Casali P.G., Sanfilippo G.R., Le Cesne A., Judson I., Blay J.Y., RayCoquard I., Nieto A., Tercere J.C., Jemeno J., Robert J., Pourquier P.: ERCC5/XPG, ERCC1, and
BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer 2011;
117: 3445-3456
Joensuu H., De Braud F., Grignani G., De Pas T., Spitalieri G., Coco P., Spreafico C., Boselli S.,
Toffalori F., Bono P., Jalava T., Kappeler C., Aglietta M., Laurent D., Casali P.G.: Vatalanib for
metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br
J Cancer 2011; 104: 1686-1690
2010
Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, Casali PG, Gronchi A. Alveolar soft
part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single
institution. Ann Surg Oncol. 2010 Jul 1. [Epub ahead of print]
Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal
stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
2010 May;21 Suppl 5:v98-102.
Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue
sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010
May;21 Suppl 5:v198-203.
Casali PG. Do rare cancers deserve specific strategies for cancer research? Lancet Oncol. 2010
Jun;11(6):506-7.
Casali PG, Sanfilippo R, D'Incalci M. Trabectedin therapy for sarcomas. Curr Opin Oncol. 2010
Jul;22(4):342-6.
Dileo P, Pricl S, Tamborini E, Negri T, Stacchiotti S, Gronchi A, Posocco P, Laurini E, Coco P, Fumagalli
E, Casali PG, Pilotti S. Imatinib response in two GIST patients carrying two hitherto functionally
uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study. Int J
Cancer. 2010 Apr 27.
Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, Messina A, Pastorino U, Pierotti MA,
Casali PG, Pilotti S. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular
bases of tumor response. Mol Cancer Ther. 2010 May;9(5):1286-97.
Bonvalot S, Miceli R, Berselli M, Causeret S, Colombo C, Mariani L, Bouzaiene H, Le Péchoux C, Casali
PG, Le Cesne A, Fiore M, Gronchi A. Aggressive surgery in retroperitoneal soft tissue sarcoma carried
out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol. 2010
Jun;17(6):1507-14.
Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R,
Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC,
Mantovani A, D'Incalci M, Allavena P. Antitumor and anti-inflammatory effects of trabectedin on human
myxoid liposarcoma cells. Cancer Res. 2010 Mar 15;70(6):2235-44. Epub 2010 Mar 9.
Ardoino I, Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, Collini P, Stacchiotti S, Casali PG,
Gronchi A. Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. Cancer. 2010
May 15;116(10):2429-36.
Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S, Conca E, Gronchi A, Stacchiotti S, Manenti G,
Casali PG, Pierotti MA, Pilotti S. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways
in chordoma. Neuro Oncol 2010 Feb 17. [Epub ahead of print]
Gronchi A, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, Fiore M, Casali PG. Extremity Soft
Tissue Sarcoma in a Series of Patients Treated at a Single Institution: The Local Control Directly Impacts
Survival. Ann Surg 2010 Feb 2. [Epub ahead of print]
Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, Gronchi A, Casali PG. Tumor response
to sunitinib malate observed in clear-cell sarcoma. Ann Oncol 2010 Jan 21. [Epub ahead of print]
Stacchiotti S, Casali PG, Lo Vullo S, Mariani L, Palassini E, Mercuri M, Alberghini M, Pilotti S, Zanella L,
Gronchi A, Picci P. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of
patients surgically treated at two referral centers. Ann Surg Oncol. 2010; 17: 211-9.
2009
Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M. Diffuse malignant peritoneal
mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy
(HIPEC). Ann Surg Oncol. 2009 Feb;16(2):463-72.
Bielack S, Carrle D, Casali PG; ESMO Guidelines Working Group. Osteosarcoma: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009 May;20 Suppl 4:137-9.
Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group.
Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and followup. Ann Oncol. 2009 May;20 Suppl 4:64-7.
Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY; ESMO Guidelines Working Group. Soft tissue
sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009
May;20 Suppl 4:132-6.
Conca E, Negri T, Gronchi A, Fumagalli E, Tamborini E, Pavan GM, Fermeglia M, Pierotti MA, Pricl S,
Pilotti S. Activate and resist: L576P-KIT in GIST. Mol Cancer Ther. 2009 Sep;8(9):2491-5.
Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P,
Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A,
Fumagalli E, Reichardt P. A phase I study of single-agent nilotinib or in combination with imatinib in
patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res. 2009 Sep
15;15(18):5910-6.
Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG,
Gronchi A. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal
stromal tumors (GIST). Eur J Surg Oncol. 2009 Jul;35(7):739-45.
Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Péchoux C, Casali PG, Le Cesne A, Gronchi A,
Bonvalot S. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical
treatment. Ann Surg Oncol. 2009 Sep;16(9):2587-93.
Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A,
Aman P, Casali P, D'Incalci M, Pilotti S, Mantovani R. Trabectedin (ET-743) promotes differentiation in
myxoid liposarcoma tumors. Mol Cancer Ther. 2009 Feb;8(2):449-57.
George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan
JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD. Clinical evaluation of continuous daily dosing of
sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J
Cancer. 2009 Jul;45(11):1959-68.
Gronchi A, Bonvalot S, Le Cesne A, Casali PG. Resection of uninvolved adjacent organs can be part of
surgery for retroperitoneal soft tissue sarcoma. J Clin Oncol. 2009 Apr 20;27(12):2106-7; author reply
2107-8.
Gronchi A, Judson I, Nishida T, Poveda A, Martin J, Reichardt P, Casali PG, Cesne AL, Hohenberger P,
Blay JY. Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf
of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma
Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the
Spanish Sarcoma Group (GEIS). Eur J Cancer. 2009 May;45(7):1103-6.
Gronchi A, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E, Mariani L,
Casali PG. Aggressive surgical policies in a retrospectively reviewed single-institution case series of
retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009 Jan 1;27(1):24-30.
Grosso F, Sanfilippo R, Virdis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J,
D'Incalci M, Gronchi A, Pilotti S, Casali PG. Trabectedin in myxoid liposarcomas (MLS): a long-term
analysis of a single-institution series. Ann Oncol. 2009 Aug;20(8):1439-44.
Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, Issels R, Judson I,
Schoffski P, Leyvraz S, Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed
by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated
with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol. 2009 Aug
20;27(24):3969-74.
Lessnick SL, Dei Tos AP, Sorensen PH, Dileo P, Baker LH, Ferrari S, Hall KS. Small round cell
sarcomas. Semin Oncol. 2009 Aug;36(4):338-46.
Mertens F, Antonescu CR, Hohenberger P, Ladanyi M, Modena P, D'Incalci M, Casali PG, Aglietta M,
Alvegård T. Translocation-related sarcomas. Semin Oncol. 2009 Aug;36(4):312-23..
Micheli A, Sanz N, Mwangi-Powell F, Coleman MP, Neal C, Ullrich A, Travado L, Santini LA, Grassi L,
De Lorenzo F, Costa A, Dangou JM, Bisanti L, Seniori Costantini A, Abu-Rmeileh N, Kamal M, Federico
M, Saracci R, Rennert G, Stefanini A, Cavalli F, Cazap E, Redmond K, O'Reilly S, Muti P, Casali P,
Gatta G, Ferrari A, Koifman S, Bah E, Pastore G, Barr R, Lombardo C, Frazzingaro C, Ciampichini R,
Baili P; ICCC-3 Session B Group. International collaborations in cancer control and the Third
International Cancer Control Congress. Tumori. 2009 Sep-Oct;95(5):579-96.
Negri T, Bozzi F, Conca E, Brich S, Gronchi A, Bertulli R, Fumagalli E, Pierotti MA, Tamborini E, Pilotti
S. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated
gastrointestinal stromal tumours (GISTs). J Pathol. 2009 Jan;217(1):103-12.
Paulussen M, Bielack S, Jürgens H, Casali PG; ESMO Guidelines Working Group. Ewing's sarcoma of
the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009
May;20 Suppl 4:140-2.
Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, Piovesan C, Dileo P, Torri V,
Gronchi A, Casali PG. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to
assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.
Radiology. 2009 May;251(2):447-56.
Stacchiotti S, Marrari A, Tamborini E, Palassini E, Virdis E, Messina A, Crippa F, Morosi C, Gronchi A,
Pilotti S, Casali PG. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol. 2009
Nov;20(11):1886-94.
Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A,
Pierotti MA, Casali PG, Pilotti S. Response to sunitinib malate in advanced alveolar soft part sarcoma.
Clin Cancer Res. 2009 Feb 1;15(3):1096-104.